[go: up one dir, main page]

GB2422311A - Treatment of blood to cure disease - Google Patents

Treatment of blood to cure disease Download PDF

Info

Publication number
GB2422311A
GB2422311A GB0501156A GB0501156A GB2422311A GB 2422311 A GB2422311 A GB 2422311A GB 0501156 A GB0501156 A GB 0501156A GB 0501156 A GB0501156 A GB 0501156A GB 2422311 A GB2422311 A GB 2422311A
Authority
GB
United Kingdom
Prior art keywords
disease
cure
immune system
patient
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0501156A
Other versions
GB0501156D0 (en
GB2422311A8 (en
Inventor
Martin Lister
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB0501156A priority Critical patent/GB2422311A/en
Publication of GB0501156D0 publication Critical patent/GB0501156D0/en
Publication of GB2422311A publication Critical patent/GB2422311A/en
Publication of GB2422311A8 publication Critical patent/GB2422311A8/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3687Chemical treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Anesthesiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method of treating a sample of blood from a diseased patient wherein said blood is subjected to acid or alkaline treatment. The blood is then returned to the patient to stimulate an immune response.

Description

A General Cure To Diseases which does rMt use a horse or an egg.
Diseased matter cells which could be dotain from the blood of the patient and 5bjecting this to alkali/acid and then in solution applying this to the iuufle system of a human so that this fights the reduced strength disease and ant ibodles to the disease are thus produced from which a cure to the disease can be obtained to be used on the patient too, so that not even a chickens egg let alone a horse need be used risked cure can be tested on a petri dish using standard testing methods 50 that a human need not be risked too.
Applying this cure principle of engineerinc the mould and antibodieS this solution can be applied to animals too-

Claims (1)

  1. General Cure To Diseases Idea 3 Claims 1. Diseased matter cells which
    coula be obtained from the blood of the patient and subjecting this to alkali/acid and then in solution app!ying this to the immune system of a human so that this fights the reduced strength disease and antibodies to the disease are thus produced from which a cure to the disease can be obtained to b'e used on the patient too, so that not even a chickens egg let alone a horse need be used risked cure can be tested on a petri dish using standard testing methods so that a human need not be risked too, applying this cure principle of engineering the mould and antibodies this solution can be applied to animals too, the General Cure To Diseases Idea 3 is substantially as described herein with reference to the accompanying
    description.
    Amendments to the claims have been filed as follows General Cure To Diseases Idea 3 Claim 1. A General Cure To Diseases Idea which does not risk an egg or horse, a sample of blood of the patient is taken as it contains the disease, such as Aids, and can keep the disease alive initially, the disease in the blood is then subjected to acid/alkali bombardment by acid/alkali solution being put into the blood sample so that the disease cells outer shell is weakened, the acid/alkali bombardment is due to the disease being weakened as far as possible without i-t being destroyed this can be determined using calculus, the weakened disease cell is then put into a fresh sample of blood containing the immune system, the immune system of which attacks the weakened disease cells such that the resultant reprogrammed and strengthened immune system can combat even disease cells which have not been weakened by acid/alkali bombardment, a mould created such as by a solution of phlegm and resultant immune system on pieces of paper water milk sugar coffee tea subjected to oxygen and sunlight in a vat can thus be produced based on the resultant immune system and vat production commenced to produce further anti disease immune system by allowing the mould to grow and multiply, the mould thus produced can then in solution be tested using standard testing techniques such as seeing whether it will ward off disease cells that are pu.t in the vicinity of the mould, and then if it does it could be injected into the patient to cure the patient, the mould can be used to inoculate or vaccinate a patient, the General Cure To Diseases Idea 3 is substantially as described herein with reference to
    the accompanying description.
GB0501156A 2005-01-20 2005-01-20 Treatment of blood to cure disease Withdrawn GB2422311A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0501156A GB2422311A (en) 2005-01-20 2005-01-20 Treatment of blood to cure disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0501156A GB2422311A (en) 2005-01-20 2005-01-20 Treatment of blood to cure disease

Publications (3)

Publication Number Publication Date
GB0501156D0 GB0501156D0 (en) 2005-03-02
GB2422311A true GB2422311A (en) 2006-07-26
GB2422311A8 GB2422311A8 (en) 2006-08-18

Family

ID=34259377

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0501156A Withdrawn GB2422311A (en) 2005-01-20 2005-01-20 Treatment of blood to cure disease

Country Status (1)

Country Link
GB (1) GB2422311A (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB901431A (en) * 1958-01-20 1962-07-18 Celanese Corp Improvements in the production of cellulose triacetate filamentary materials
WO1982002841A1 (en) * 1981-02-18 1982-09-02 University Patents Inc Precipitation of proteins
EP0091784A2 (en) * 1982-04-07 1983-10-19 Baylor College of Medicine Products for use in treating cancer
EP0168801A2 (en) * 1984-07-20 1986-01-22 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Apparatus for separating proteins from blood plasma
US4663049A (en) * 1984-07-05 1987-05-05 University Of Utah Process for therapeutic dissociation of immune complexes and removal of antigens
WO1988001507A1 (en) * 1986-08-01 1988-03-10 Rubinstein Alan I A method to treat blood
WO2001080866A1 (en) * 2000-04-26 2001-11-01 Gauchet Jean Yves Immunostimulatory pharmaceutical composition and its use protocol

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB901431A (en) * 1958-01-20 1962-07-18 Celanese Corp Improvements in the production of cellulose triacetate filamentary materials
WO1982002841A1 (en) * 1981-02-18 1982-09-02 University Patents Inc Precipitation of proteins
EP0091784A2 (en) * 1982-04-07 1983-10-19 Baylor College of Medicine Products for use in treating cancer
US4663049A (en) * 1984-07-05 1987-05-05 University Of Utah Process for therapeutic dissociation of immune complexes and removal of antigens
EP0168801A2 (en) * 1984-07-20 1986-01-22 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Apparatus for separating proteins from blood plasma
EP0404202A2 (en) * 1984-07-20 1990-12-27 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Agent for separating proteins from blood plasma
WO1988001507A1 (en) * 1986-08-01 1988-03-10 Rubinstein Alan I A method to treat blood
WO2001080866A1 (en) * 2000-04-26 2001-11-01 Gauchet Jean Yves Immunostimulatory pharmaceutical composition and its use protocol

Also Published As

Publication number Publication date
GB0501156D0 (en) 2005-03-02
GB2422311A8 (en) 2006-08-18

Similar Documents

Publication Publication Date Title
MXPA02007137A (en) Liver tissue source.
US20130236428A1 (en) Reprogramming of Aged Adult Stem Cells
WO2004011631A3 (en) Methods and compositions for treating tissue defects using pulsed electromagnetic field stimulus
CN107517899A (en) The sea water pearls breeding method of seedless pattra pearl
CN105265353B (en) There are pearl nucleus of the hydrogel layer containing external carbon dosage and preparation method thereof on a kind of surface
GB2422311A (en) Treatment of blood to cure disease
EA013526B1 (en) Method for preparing delicacy foods from ovulated but not fertilized eggs of aquatic animals and delicacy foods prepared therefrom
JP4040413B2 (en) Nucleation method of pearl shell
Berman et al. The influence of the flow of detergent and donor characteristics on the extracellular matrix composition after human pancreas decellularization
CN110079575A (en) A method of extracting low molecular weight collagen from deer sinew
US11499148B2 (en) Fatty material from which immunity is removed and method for manufacturing same
CN105755001A (en) Preparation for inhibiting spreading of plant viruses and application of preparation
Mitchell Outlines of biology
WO2006110843A3 (en) Engineered deremal tissue particles and transplantation methods
WO2007106203A3 (en) Systems and methods for sanitizing egg processing equipment
CN106342443A (en) Method for enhancing white gourd seed germination rate
CN113122604A (en) Sea intestine glue and preparation method and application thereof
Li et al. Stem cells, stem cell niche and antler development
CN110117618A (en) A kind of labeling method of Sepiella maindroni archaeocyte
EP4512437A1 (en) Multi-stage decellularized tissue supplement, and preparation method thereof
Asashima et al. Self-organization from organs to embryoids by activin in early amphibian development
CN1159446C (en) A kind of fish electric pulse sperm transgenic method
CN114286694A (en) Animal adipose tissue-derived extracellular matrix and animal adipose tissue-derived extracellular matrix preservation solution
CN102188745B (en) Preparation method of medical suture thread by drawing nutria tail tendon
KR101324508B1 (en) The method of removing heterologous immunogens and retrovirus in bioscaffold

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)
APTC Appeals to the court
APTC Appeals to the court

Free format text: APPEAL DISMISSED; APPEAL WAS DISMISSED.